TCRX / FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignancies

TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank more_horizontal

TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank more_horizontal

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compare more_horizontal

Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation more_horizontal

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compare more_horizontal

Use these strategies to maximize your penny stocks profits The post 3 Top Strategies for Maximizing Penny Stock Profits Right Now appeared first on Pe more_horizontal

Shares of TScan Therapeutics Inc. TCRX powered up 43.1% in premarket trading Tuesday, after the biopharmaceutical company announced a collaboration wi more_horizontal

The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies p more_horizontal